← Back to Search

Neurosteroid

Effect of Allopregnanolone on Stress-induced Craving

Phase 1
Waitlist Available
Led By Elizabeth Ralevski, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes

Summary

This trial tests if a specific treatment can reduce stress and anxiety in heavy drinkers, potentially lowering their cravings for alcohol. The treatment has been shown to decrease alcohol consumption in animal studies.

Eligible Conditions
  • Alcoholism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Alcohol Urge Questionnaire (AUQ)
The State-Trait Anxiety Inventory (STAI-6)
Secondary study objectives
Biphasic Alcohol Effects scale (BAES)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: allopregnanoloneActive Control1 Intervention
allopregnanolone
Group II: placeboPlacebo Group1 Intervention
placebo

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,927 Previous Clinical Trials
3,031,716 Total Patients Enrolled
91 Trials studying Alcoholism
10,961 Patients Enrolled for Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
837 Previous Clinical Trials
1,083,018 Total Patients Enrolled
458 Trials studying Alcoholism
824,034 Patients Enrolled for Alcoholism
Elizabeth Ralevski, PhDPrincipal InvestigatorYale University

Media Library

Allopregnanolone (Neurosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT04015869 — Phase 1
Alcoholism Research Study Groups: allopregnanolone, placebo
Alcoholism Clinical Trial 2023: Allopregnanolone Highlights & Side Effects. Trial Name: NCT04015869 — Phase 1
Allopregnanolone (Neurosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04015869 — Phase 1
~2 spots leftby Dec 2025